RxDoctor Payments Data

Antoine Albert, MD

Family Medicine · Dallas, TXNPI 1023043924

Payments from drug & device makers

$1,502in general payments, 2019–2025

Across 72 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$359
  • Novo Nordisk$276
  • Inspire Medical Systems, Inc.$171
  • Bayer$147
  • GM Pharmaceuticals, Inc.$121
  • Boehringer Ingelheim$99
  • plus $329 from 10 others

What the payments were for

  • Food & beverage$1,502100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,502 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,479
Medicare patients
74
Services billed
2,593

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol44$44,603
OzempicSemaglutide15$21,636
JardianceEmpagliflozin18$16,622
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$13,257
EliquisApixaban11$9,000
Atorvastatin Calcium137$1,120
Gabapentin35$764
Losartan Potassium57$588
Dicyclomine Hcl19$575
Tamsulosin Hcl47$568
Albuterol Sulfate HfaAlbuterol Sulfate20$480
Metformin Hcl95$476
Levothyroxine Sodium61$462
Lisinopril82$441
Amlodipine Besylate59$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$359$57,86163 claims
Novo NordiskOzempic$276$21,63615 claims
Boehringer IngelheimJardiance$99$16,62218 claims
PfizerEliquis$49$9,00011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →